Track topics on Twitter Track topics that are important to you
Ireland-domiciled drugmaker Shire is considering splitting off its neuroscience division into a separate, publicly listed company. The move, revealed during its second-quarter results presentation, is one of several strategic options Shire is currently assessing for its neuroscience franchise, which achieved sales of $2.49 billion in 2016, the vast majority from medicines to treat attention deficit hyperactivity disorder (ADHD).
Original Article: Shire Mulls Separation of NeurosciencesNEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
Attention deficit hyperactivity disorder (ADHD)
Attention deficit hyperactivity disorder (ADHD) is a group of behavioural symptoms that include inattentiveness, hyperactivity and impulsiveness. Attention deficit disorder (ADD) is a sub-type of ADHD - symptoms of ADHD include: a short attenti...
Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...